Gore debuts enhanced stent-graft
This article was originally published in The Gray Sheet
W.L. Gore launches Viabahn stent graft endoprosthesis with heparin bioactive surface Sept. 4, following PMA approval July 31. The device is used for vascular bypass in the superficial femoral artery. With about 80,000 such procedures a year, the market is worth roughly $150 million, Gore says. The device's anticoagulant heparin-bonded surface improves on the original model, approved in June 2005. Marketing will be targeted at interventional cardiologists, vascular surgeons and interventional radiologists...
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.